
Bin-Chi Liao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5789842/publications.pdf Version: 2024-02-01



RIN-CHILIAO

#	Article	IF	CITATIONS
1	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology, 2015, 10, 1754-1761.	1.1	145
2	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 94-101.	2.4	126
3	Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 50-61.	1.1	56
4	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. European Journal of Cancer, 2020, 124, 110-122.	2.8	56
5	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Biomedical Science, 2016, 23, 86.	7.0	41
6	Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer, 2017, 110, 7-13.	2.0	40
7	Lung Cancer in Republic of China. Journal of Thoracic Oncology, 2021, 16, 519-527.	1.1	34
8	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clinical Cancer Research, 2022, 28, 1560-1571.	7.0	33
9	Second-line treatment of <i>EGFR</i> T790M-negative non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	3.2	28
10	Treating patients with <i>ALK</i> -positive non-small cell lung cancer: latest evidence and management strategy. Therapeutic Advances in Medical Oncology, 2015, 7, 274-290.	3.2	20
11	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist, 2020, 25, 702-711.	3.7	17
12	CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 1231-1242.	1.1	16
13	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Current Oncology Reports, 2017, 19, 4.	4.0	15
14	Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. Clinical Lung Cancer, 2015, 16, 137-143.	2.6	14
15	First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs, 2013, 73, 357-369.	10.9	12
16	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association, 2018, 117, 326-331.	1.7	10
17	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. Journal of Cancer, 2016, 7, 1515-1523.	2.5	9
18	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. Expert Opinion on Pharmacotherapy, 2018, 19, 851-864.	1.8	6

Βιν-Chi Liao

#	Article	IF	CITATIONS
19	Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis. Medical Oncology, 2017, 34, 143.	2.5	6
20	Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis Journal of Clinical Oncology, 2021, 39, 6024-6024.	1.6	3
21	A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE) Journal of Clinical Oncology, 2020, 38, TPS9631-TPS9631.	1.6	2
22	Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1426-1428.	1.1	0
23	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC. JTO Clinical and Research Reports, 2021, 2, 100099.	1.1	0
24	Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis Journal of Clinical Oncology, 2015, 33, e19061-e19061.	1.6	0
25	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. Translational Lung Cancer Research, 2012, 1, 227-9.	2.8	0